Split History
ETFs Holding APRI »    APRI Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Apricus Biosciences is a biopharmaceutical company focused on the development of product candidates in the areas of urology and rheumatology. Co. has two product candidates in development; Vitaros, a topically-applied cream formulation of alprostadil under development for the treatment of erectile dysfunction, which Co. in-licensed from Warner Chilcott Company, Inc.; and RayVa, a topically-applied cream formulation of alprostadil designed to dilate blood vessels in development for the treatment of Raynaud's Phenomenon, secondary to scleroderma, for which it owns worldwide rights. According to our APRI split history records, Apricus Biosciences has had 1 split.
APRI split history picture
Apricus Biosciences (APRI) has 1 split in our APRI split history database. The split for APRI took place on October 24, 2016. This was a 1 for 10 reverse split, meaning for each 10 shares of APRI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as Apricus Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the APRI split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Apricus Biosciences shares, starting with a $10,000 purchase of APRI, presented on a split-history-adjusted basis factoring in the complete APRI split history. APRI split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/20/2007
End date: 09/19/2017
Start price/share: $15.40
End price/share: $1.75
Dividends collected/share: $0.00
Total return: -88.64%
Average Annual Total Return: -19.54%
Starting investment: $10,000.00
Ending investment: $1,135.75
Years: 10.01
Date Ratio
10/24/20161 for 10
APRI is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ARA Split History
ARNA Split History
ARTC Split History
ARWR Split History
ASMB Split History
ASTM Split History
ATE Split History
ATEC Split History
ATOS Split History
ATRC Split History

Mer Telemanagement Solutions Ltd. (MTSL)
Merrimack Pharmaceuticals (MACK)
Diana Containerships Inc. (DCIX)
Farmers & Merchants Bancorp, Inc. (FMAO)
Henry Schein, Inc. (HSIC)
Intuitive Surgical, Inc. (ISRG)
Diana Containerships Inc. (DCIX)
Bridgeline Digital, Inc. (BLIN)
SUPERVALU INC. (SVU)
DryShips Inc. (DRYS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

APRI Insider Buying

APRI Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.